[go: up one dir, main page]

WO2024238709A3 - Inhibiteurs à petites molécules de p27 - Google Patents

Inhibiteurs à petites molécules de p27 Download PDF

Info

Publication number
WO2024238709A3
WO2024238709A3 PCT/US2024/029543 US2024029543W WO2024238709A3 WO 2024238709 A3 WO2024238709 A3 WO 2024238709A3 US 2024029543 W US2024029543 W US 2024029543W WO 2024238709 A3 WO2024238709 A3 WO 2024238709A3
Authority
WO
WIPO (PCT)
Prior art keywords
small molecule
subject
molecule inhibitors
need
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/029543
Other languages
English (en)
Other versions
WO2024238709A2 (fr
Inventor
Robert J. Devita
Grace Y. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concarlo Therapeutics Inc
Original Assignee
Concarlo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concarlo Therapeutics Inc filed Critical Concarlo Therapeutics Inc
Priority to AU2024271540A priority Critical patent/AU2024271540A1/en
Publication of WO2024238709A2 publication Critical patent/WO2024238709A2/fr
Publication of WO2024238709A3 publication Critical patent/WO2024238709A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés à petites molécules utiles pour le traitement du cancer, et des compositions pharmaceutiques contenant de tels composés. L'invention concerne également des méthodes de traitement du cancer chez un sujet en ayant besoin, comprenant l'administration d'une quantité thérapeutiquement efficace d'un composé de la présente invention à un sujet en ayant besoin.
PCT/US2024/029543 2023-05-18 2024-05-15 Inhibiteurs à petites molécules de p27 Pending WO2024238709A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024271540A AU2024271540A1 (en) 2023-05-18 2024-05-15 Small molecule inhibitors of p27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363467561P 2023-05-18 2023-05-18
US63/467,561 2023-05-18

Publications (2)

Publication Number Publication Date
WO2024238709A2 WO2024238709A2 (fr) 2024-11-21
WO2024238709A3 true WO2024238709A3 (fr) 2025-05-30

Family

ID=93520146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/029543 Pending WO2024238709A2 (fr) 2023-05-18 2024-05-15 Inhibiteurs à petites molécules de p27

Country Status (2)

Country Link
AU (1) AU2024271540A1 (fr)
WO (1) WO2024238709A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050048A1 (fr) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Cyclohexyldiamines utilises en tant qu'antagonistes selectifs du recepteur adrenergique alpha 1a/1d pour le traitement de l'hypertrophie benigne de la prostate et des dysfonctionnements du bas appareil urinaire
WO2011002817A1 (fr) * 2009-06-29 2011-01-06 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
WO2011072174A1 (fr) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
WO2014207508A1 (fr) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Composé pyridylique approprié pour le traitement de troubles métaboliques
WO2016022521A1 (fr) * 2014-08-07 2016-02-11 Vitae Pharmaceuticals, Inc. Dérivés de pipérazine comme modulateurs du récepteur hépatique x

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050048A1 (fr) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Cyclohexyldiamines utilises en tant qu'antagonistes selectifs du recepteur adrenergique alpha 1a/1d pour le traitement de l'hypertrophie benigne de la prostate et des dysfonctionnements du bas appareil urinaire
WO2011002817A1 (fr) * 2009-06-29 2011-01-06 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
WO2011072174A1 (fr) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs destinés au traitement d'un cancer caractérisé par une mutation idh
WO2014207508A1 (fr) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Composé pyridylique approprié pour le traitement de troubles métaboliques
WO2016022521A1 (fr) * 2014-08-07 2016-02-11 Vitae Pharmaceuticals, Inc. Dérivés de pipérazine comme modulateurs du récepteur hépatique x

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM COMPOUND 28 January 2016 (2016-01-28), XP093318331, Database accession no. 112983967 *

Also Published As

Publication number Publication date
WO2024238709A2 (fr) 2024-11-21
AU2024271540A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
PH12022550343A1 (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
DK0677039T3 (da) Cyclobutanderivater som squalen-syntetase- og protein-farnesyltransferaseinhibitorer
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
SE0300119D0 (sv) Novel compounds
EP1090908A3 (fr) Derives de cyclobutane utilisés comme inhibiteurs de la protéine farnesyltransferase
MXPA03008756A (es) Derivados de n-(arilsulfonil) beta-aminoacidos que comprenden un grupo aminometilo substituido, el metodo de preparacion de los mismos y las composiciones farmaceuticas que los contienen.
WO2007112000A3 (fr) Traitement de la douleur
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
IL294247B1 (en) (2r,4r)-1-(3-chloro-2-fluorobenzyl)-4-((5-fluoro-4-methyl-6-((5-methyl-1h-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid and a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof
CA2301742A1 (fr) Pyridines 2,3,5-trisubstituees utilisees comme inhibiteurs de la cyclo-oxygenase 2
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
WO2024006726A3 (fr) Composés utilisés en tant qu'inhibiteurs d'axl
WO2004011477A3 (fr) Ketolides pontes aux carbones 6,11-4
WO2022104153A3 (fr) Composés et méthodes de traitement d'infections virales
TW200639159A (en) Treatment of pain
CA2211320A1 (fr) 5-methanesulfonamido-3h-isobenzofuran-1-ones utilises comme inhibiteurs de cyclooxygenase-2
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
WO2024020534A3 (fr) Composés cycliques et leurs procédés d'utilisation
WO2024238709A3 (fr) Inhibiteurs à petites molécules de p27
WO2023150291A3 (fr) Composés hétérocycliques et procédés d'utilisation
CR20240016A (es) Compuestos terapéuticos y procedimientos
CA2301590A1 (fr) 2-aminopyridines utilisees comme inhibiteurs de la cyclo-oxygenase 2
MX2023004435A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis.
AU2002362008A1 (en) Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
CA3156074C (fr) Inhibiteurs de mll1 et agents anticancereux

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024271540

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024271540

Country of ref document: AU

Date of ref document: 20240515

Kind code of ref document: A